SLFN11 and cancer: There is a proposal to use the expression of SLFN11 as a dual biomarker, capturing simultaneously immunological and cancer cell-intrinsic functional dispositions associated with sensitivity to DNA-damaging treatment in high-grade serous ovarian cancer patients [16].